Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride

Indian Journal of Physiology and Pharmacology

Volumn 52, Issue 1, 2008, Pages 43-52

  Bhattacharya, S K ^a   Madan, M ^b   Mahajan, P ^b   Paudel, K R ^a   Rauniar, G P ^a   Das, B P ^a   Roy, R K ^a  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Glibenclamide; Glimepiride; Glycaemic control; Plasma insulin; Plasma leptin; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; ASTHENIA; BODY MASS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; BLOOD GLUCOSE; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; MALE; PATIENT COMPLIANCE; SULFONYLUREA COMPOUNDS; WAIST-HIP RATIO;

EID: 44949246569     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Groop LC. Pathogenesis of insulin resistance in type 2 diabetes: a collision between thrifty genes and an affluent environment. Drugs 1999; 58(Suppl 1): 11-12.
2. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177-269.
3. Rosskamp R, Wernicke-Panten K, Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Drug Res Clin Pract 1996; 31(Suppl) S33-S34.
4. Auwerx J, Staels B. Leptin. Lancet 1998; 351: 737-742.
5. Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-1462.
6. Zimmet P, Alberti KGMM. Leptin: is it important in diabetes? Diab Med 1996; 13: 501-503.
7. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
8. Erickson JC, Hollopeter G, Pajmiter R. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-1707.
9. Kulkarni SK, Kaur G. Obesity: an insight into its neurochemical basis and treatment. Ind J Pharmacol 1999: 31: 388-403.
10. Saladin R, DeVos P, GuerreMillo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-529.
11. Wabitsch M, Jensen PE, Blum WF, et al. Insulin and cortisol promote leptin production in cultured human fat cell. Diabetes 1996; 45: 1435-1438.
12. Nolan JJ, Olefsky JM, Nyce MR, et al. Effect of troglitazone on leptin production studies in vitro and in human subjects. Diabetes 1996; 45: 1276-1278.
13. Dagogo-Jack S, Fanelli C, Paramore D, et al. Plasma leptin and insulin relationships in obese and non-obese humans. Diabetes 1996; 45: 695-698.
14. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-295.
15. Malmstroem R, Taskines MR, Karonen F, et al. Insulin increases plasma leptin concentration in normal subjects and patients with NIDDM. Diabetologia 1996; 39: 993-996.
16. Aiston S, Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin. Diabetes 1999; 48: 15-20.
17. Burcelin R, Kamohara S, Li J, et al. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake on ob/ob mice. Diabetes 1999; 48: 1264-1269.
18. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin deficient diabetes in rats. Diabetes 1999; 48: 1487-1492.
19. Haynes WG, Sivitz WI, Morgan DA, et al. Sympathetic and cardio-renal actions of leptin. Hypertension 1997; 30 (2): 619-623.
20. Mohammad Ali V, Pinkney JH, Panahloo A, et al. Relationships between plasma leptin and insulin concentrations, but not insulin resistance, in non-insulin dependent (type 2) diabetes mellitus. Diab Med 1997; 14: 376-380.
21. World Health Organization. Diabetes mellitus: report of WHO study group. Tech Rep Ser No. 727 Geneva; World Health Organization, 1985; 7-133.
22. Shoji T, Nishizawa Y, Emoto M, et al. Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM. Diabetologia 1997; 40: 676-679.
23. Widajaja A, Stratton IM, Horn R, et al. UK PDS 20: plasma leptin, obesity and plasma insulin in type 2 diabetic subjects. J Clin Endocrinal Metab 1997; 82: 654-657.
24. 1C in patients with non-insulin dependent diabetes mellitus. Diab Res Clin Prac 1999: 43: 187-191.
25. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight reduced subjects. Nature Med 1995; 1: 1155-1161.
26. Schwartz MW, Prigeon RL, Kahn SE, et al. Evidence that plasma leptin and insulin are associated with body adiposity via different mechanisms. Diabetes Care 1997; 20: 1476-1481.
27. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188.
28. Muller G, Ertl J, Gerl E, et al. Leptin impairs metabolic actions of insulin in rat adipocytes. J Biol Chem 1997; 272: 10585-10593.
29. Massilon D, Barzilai N, Vuguin P, et al. Leptin acutely modulates hepatic gene expression, glucose fluxes and insulin action. Diabetes 1997; 46: 345-347.
30. Shalev A, Vosmeer S, Keller U. Absence of short term effects of GLP-1 and of hyperglycemia on plasma leptin levels in man. Metabolism 1997; 46: 723-725.
31. Ostlund RE Jr, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet and metabolic covariates. J Clin Endocrinol Metab 1996; 81: 3909-3913.
32. Melander A, Bitzen PO, Faber O, et al. Sulphonylurea anti diabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72.
33. Groop LC, Defronzo RA. Sulphonylureas. In: Current Management of Diabetes. Eds. Defronzo RA St. Louis (MO): Mosby- Year Book Inc. 1998: 96-101.
34. Haffner SM, Hanefeld M, Fischer S, et al. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subject with NIDDM. Diabetes Care 1991; 20: 430-434.